Shalby Limited — Updates, 04-02-2025: Press Release

Shalby Limited has reported a solid consolidated performance for Q3 FY2025, with revenue surging to ₹2811 million, reflecting a year-on-year growth of 27.4%. The EBITDA reached ₹393 million, while profit before tax (PBT) stood at ₹124 million. Key operational metrics showed a 7.9% year-on-year increase in in-patient count, totaling 22,369, and an ARPOB of ₹42,704, up 14.4% from the previous year. The growth was supported by the implant business and the acquisition of a hospital in Delhi NCR. Standalone revenue increased by 13.3% to ₹227 crores, with an EBITDA margin of 21.5%. The company's Homecare business added ₹3.6 crores, and over 1000 students enrolled in healthcare programs at Shalby Academy. With net debt at ₹2667 million and a net cash balance of ₹660 million, Shalby is well-placed for strategic growth initiatives. The recent inauguration of the Shalby Bone and Tissue Bank marks another step in enhancing its service offerings and operational capabilities. Positive outlook ahead with ongoing efforts for expansion and operational efficiency.